Literature DB >> 1709644

Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis.

J W Rose1, H Lorberboum-Galski, D Fitzgerald, R McCarron, K E Hill, J J Townsend, I Pastan.   

Abstract

IL2-PE40 is a chimeric protein composed of human interleukin-2 (IL2) genetically fused to a modified form of Pseudomonas exotoxin lacking the cell recognition domain. IL2-PE40 is cytotoxic for IL2 receptor-bearing lymphocytes in culture and can inhibit activation of T cells in vivo. IL2-PE40 can significantly diminish antigen-stimulated proliferation of lymphocytes sensitized to myelin basic protein. Intraperitoneal administration of IL2-PE40 not only markedly inhibits the clinical manifestations of adoptively transferred relapsing experimental allergic encephalomyelitis but also dramatically reduces both inflammation and demyelination characteristic of the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709644     DOI: 10.1016/0165-5728(91)90190-i

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  6 in total

1.  Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.

Authors:  Monica A Rojas; Noel G Carlson; Thomas L Miller; John W Rose
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

Review 2.  Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis.

Authors:  Laura E Baldassari; John W Rose
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

3.  Effect of IL-2-Bax, a novel interleukin-2-receptor-targeted chimeric protein, on bleomycin lung injury.

Authors:  Michael J Segel; Rami Aqeilan; Keren Zilka; Haya Lorberboum-Galski; Shulamit B Wallach-Dayan; Michael W Conner; Thomas G Christensen; Raphael Breuer
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

Review 4.  Monoclonal antibody treatments for multiple sclerosis.

Authors:  John W Rose; John Foley; Noel Carlson
Journal:  Curr Neurol Neurosci Rep       Date:  2008-09       Impact factor: 6.030

5.  Monoclonal antibody treatments for multiple sclerosis.

Authors:  John W Rose; John F Foley; Noel G Carlson
Journal:  Curr Treat Options Neurol       Date:  2009-05       Impact factor: 3.972

Review 6.  Multiple sclerosis.

Authors:  S G Lynch; J W Rose
Journal:  Dis Mon       Date:  1996-01       Impact factor: 3.800

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.